UNITED THERAPEUTICS Corp (UTHR) Stock
UTHR has an Alpha Score of 65 out of 100 (moderate), computed on Oct 30, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 5 trades in UTHR since 2019: 2 purchases and 3 sales, most recently Lisa McClain (sale, Oct 31, 2025). 8 of the hedge funds AlphaScala tracks reported UTHR in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $925.85M. Company insiders reported 0 open-market buys and 817 sales on SEC Form 4 in the 90 days to Nov 2, 2026. Its trailing P/E ratio is 18.2 and its net margin 41.6% (key statistics as of Oct 22, 2026).
What is UTHR's Alpha Score?
How it works →Alpha Score of 65 reflects moderate overall profile with strong momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded UNITED THERAPEUTICS Corp (UTHR)?
Most recent: Lisa McClain (sale, Oct 31, 2025); records start Mar 6, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-11 | purchase | $1k – $15k |
| Donna Shalala D-FL · House | 2019-03-06 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026.
See all UTHR political trades →Which hedge funds own UTHR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.71M | $925.85M | -4% |
| Millennium Management Israel Englander | 409K | $221.65M | +167% |
| Citadel Ken Griffin | 305K | $165.09M | -16% |
| Point72 Steve Cohen | 201K | $108.99M | +35% |
| Bridgewater Associates Ray Dalio | 111K | $60.32M | +0% |
| Marshall Wace | 30K | $16.38M | -60% |
| Hussman Investment Trust John Hussman | 6K | $3.41M | +200% |
| Blackstone | 2K | $982.3K | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are UNITED THERAPEUTICS Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 119 | $71K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 728 | $434K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 393 | $235K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 1.5K | $895K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 884 | $529K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 1.2K | $720K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 1.7K | $1.0M |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 2.0K | $1.2M |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 577 | $348K |
| Oct 30, 26 | Rothblatt Martine A | Chairperson & CEO | SELL | 183 | $111K |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are UTHR's key statistics?
Key statistics as of Oct 22, 2026
How does UTHR's valuation compare with the Healthcare sector?
| Metric | UTHR | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 18.2 | 27.2 | 99 |
| Net margin | 41.56% | 4.85% | 143 |
| Return on equity | 20.18% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
UTHR price chart
Powered by TradingViewWhat does UNITED THERAPEUTICS Corp do?
United Therapeutics Corporation is a biotechnology company specializing in therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, and other serious conditions. Founded in 1996 and headquartered in Silver Spring, Maryland, the company operates as a public benefit corporation focused on developing innovative treatments and technologies. Its FDA-approved therapeutic portfolio includes Tyvaso (treprostinil), available in both inhalation powder and nebulized formulations; Remodulin Injection; Orenitram Extended-Release Tablets; Adcirca (tadalafil); and Unituxin for treating PAH and related conditions. Beyond traditional pharmaceuticals, United Therapeutics pursues transformational initiatives through its subsidiary Lung Biotechnology PBC to address the critical shortage of transplantable organs through xenotransplantation and bioengineering technologies. The company maintains a robust commercial presence, distributing products through healthcare provider networks and partnerships. Its pipeline includes clinical programs exploring new therapeutic indications, delivery mechanisms, and organ manufacturing solutions. United Therapeutics serves patients, healthcare providers, and research institutions globally, combining steady commercial performance with visionary medical innovation.